23andMe Special Committee Announces Exploration of Strategic Alternatives

Core Viewpoint - 23andMe Holding Co. is exploring strategic alternatives, which may include a potential sale of the company or other strategic actions [1][2]. Group 1: Strategic Alternatives - The Special Committee of the Board of Directors has been formed to review available strategic alternatives for 23andMe [2]. - The company has engaged Moelis & Company LLC as its financial advisor and Goodwin Procter LLP as its legal advisor for this process [2]. Group 2: Future Expectations - There is no assurance that the exploration of strategic alternatives will lead to any agreements or transactions [3]. - 23andMe does not plan to provide updates on this process until definitive agreements are reached or additional disclosure is legally required [3]. Group 3: Company Overview - 23andMe is a genetics-led consumer healthcare and research company focused on empowering a healthier future [4].